62nd ASH Annual Meeting and Exposition: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I

Oral and Poster Abstracts
Poster

Adult, ALL, AML, antibodies, Biological, Leukemia, survivorship, therapy sequence, bone marrow, CML, Diseases, Non-Biological, Bone Marrow Failure, Combinations, Elderly, Therapies, Adverse Events, chemotherapy, MDS, Pediatric, enzyme inhibitors, MPN, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , TKI

1662

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Thomas G. Knight, MD¹, Melissa Aguiar, MSN, RN²^*, Myra Robinson, MSPH³^*, Allison Martin, PharmD¹^*, Tommy Chen, BS³^*, Rupali Bose, MS, MBA³^*, Jing Ai, MD, PhD¹, Brittany K. Ragon, MD¹, Aleksander L. Chojecki¹, Nilay A. Shah, MD¹^*, Srinivasa R. Sanikommu, MD¹, James Symanowski, PhD³^*, Edward A Copelan¹ and Michael R. Grunwald, MD¹

¹Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
²Levine Cancer Institute, Atrium Health, Charlotte, NC
³Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC

1663

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Gregory A. Abel, MD, MPH¹, Donnie Hebert, PhD²^*, Cecilia Lee, DrPH, RN³^*, James M. Foran, MD⁴, Steven D. Gore, MD⁵, Wael Saber, MD, MS⁶, Dana Elise Rollison, PhD⁷^*, Eric Padron, MD⁸, Steffanie H. Wilson, PhD⁹^*, Jason Thompson, MS, MBA⁹^*, Myron Waclawiw, PhD¹⁰^*, Nancy L. DiFronzo, PhD¹⁰^* and Mikkael A. Sekeres¹¹

¹Dana-Farber Cancer Institute, Boston, MA
²The Emmes Company, LLC, Hamburg, NY
³National Cancer Institute, Rockville, MD
⁴Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
⁵NIH/NCI Cancer Therapy Evaluation Program, Rockville, MD
⁶CIBMTR, Medical College of Wisconsin, Milwaukee, WI
⁷Moffitt Cancer Center and Research Institute, Tampa, FL
⁸Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁹The Emmes Company, LLC, Rockville, MD
¹⁰National Heart, Lung, and Blood Institute, National Institutes of Health, Division of Blood Diseases & Resources, Bethesda, MD
¹¹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1664

Improving Understanding of MDS Using an Animated Patient’s Guide to Benefit Patient Health Outcomes

David A. Sallman, MD^1,2, Tracey Iraca³^*, Casey L. O'Connell, MD⁴, Rafael Bejar, MD, PhD⁵ and Sandra Kurtin, ANP⁶

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²H. Lee Moffitt Cancer Center, Tampa, FL
³MDS Foundation, Inc., Yardville, NJ
⁴University of Southern California, Los Angeles, CA
⁵Moores Cancer Center, University of California, San Diego, La Jolla, CA
⁶The University of Arizona Cancer Center, Tucson, AZ

1665

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD, PhD, MPH¹, Xiting Cao²^*, Islam Sadek²^*, Rodrigo Maegawa, MD²^*, Dominick Latremouille-Viau, MSc³^*, Irina Pivneva³^*, Annie Guerin³^* and B. Douglas Smith, MD⁴

¹Cleveland Clinic, Cleveland, OH
²Novartis Pharmaceuticals Corporation, East Hanover, NJ
³Analysis Group, Inc., Montreal, QC, Canada
⁴Division of Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD

1666

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Ajeet Gajra, MD, MBBS, Marjorie E Zettler, PhD, MPH^*, Andrew J Klink, PhD, MPH^* and Bruce Feinberg, DO

Cardinal Health Specialty Solutions, Dublin, OH

1667

A Pilot Review of Outcomes in Pediatric MDS: Validating Methods for a North American Multicenter Study

Orlando Esparza, MD¹, Kristen Campbell²^* and Taizo A. Nakano, MD¹

¹Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO
²Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO

1668

A Retrospective Analysis of Outcomes Following Allogeneic Stem Cell Transplantation for Patients from Appalachian Counties

Amneet Bajwa, MD, MBA¹^*, Qiuhong Zhao, MS²^*, Joseph Coleman³^*, Jonathan E Brammer, MD⁴, Hannah Choe, MD^5,6, Yvonne A. Efebera, MD, MPH⁷, Karilyn Larkin, MD⁵, Alice S. Mims, MD⁸, Sam Penza, MD^3,5, Ayman Saad, MD⁵, Sumithira Vasu, MD, MBBS⁹, Sarah A Wall, MD² and Samantha Jaglowski, MD, MPH^9,10

¹Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
²Division of Hematology, The Ohio State University, Columbus, OH
³Hematology, The Ohio State University, Columbus, OH
⁴The Ohio State University James Comprehensive Cancer Center, Columbus, OH
⁵Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁶The Ohio State University Comprehensive Cancer Center, Columbus
⁷Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁸The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁹The Ohio State University, Columbus, OH
¹⁰The James Cancer Hospital and Solove Research Institute of The Ohio State University Comprehensive Cancer Center, Columbus, OH

1669

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Jan Philipp Bewersdorf, MD¹, Stephanie Prozora, BS, MD², Rong Wang, PhD^3,4^*, Nikolai A. Podoltsev, MD, PhD^3,5, Rory M. Shallis, MD⁶, Scott F. Huntington, MD, MPH^7,8, Natalia Neparidze, MD^9,10, Xiaomei Ma, PhD¹¹^*, Steven D. Gore, MD^3,12, Amer M. Zeidan, MBBS, MHS^13,14 and Amy J. Davidoff, PhD^7,15^*

¹Department of Internal Medicine, Yale University, New Haven, CT
²Yale School of Medicine, New Haven, CT
³Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT
⁴Yale University School of Public Health, New Haven, CT
⁵Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT
⁶Yale Cancer Center, West Haven, CT
⁷Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
⁸Yale Cancer Center, Yale University School of Medicine, New Haven, CT
⁹Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT
¹⁰Section of Hematology, Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT
¹¹School of Public Health, Yale University, New Haven, CT
¹²Yale Cancer Center, New Haven, CT
¹³Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center,, Yale University, New Haven, CT
¹⁴Yale University School of Medicine and Yale Cancer Center, New Haven, CT
¹⁵Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT

1670

Analysis of Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Acute Myeloid Leukemia

Terrence F. Fagan¹^*, Farhad Ravandi, MBBS², B. Douglas Smith, MD³, Roland P Walter, MD PhD⁴, Eunice S. Wang, MD⁵, Timothy A Quill, PhD¹^*, Kevin L Obholz¹^* and Jeffrey E. Lancet, MD⁶

¹Clinical Care Options, LLC, Reston, VA
²Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
³Johns Hopkins Medical Institutes, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD
⁴Department of Medicine, University of Washington, Seattle, WA
⁵Roswell Park Comprehensive Cancer Center, BUFFALO, NY
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

906.P1.27 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I